Tysabri (natalizumab) Market Analysis 2026: Market Size, Growth Trends And Industry Outlook
Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Tysabri (natalizumab) Market Growth Potential: How Will Market Size Shift Through 2030?
The market for tysabri (natalizumab) has experienced significant expansion in recent years. It is projected to increase from $2.66 million in 2025 to $2.87 million in 2026, demonstrating a compound annual growth rate (CAGR) of 8.1%. The historical rise can be attributed to several factors, including the increasing prevalence of multiple sclerosis, the approval of natalizumab as a therapy, its adoption by neurologists, the persistent unmet need in aggressive MS, and the expansion of infusion centers.
The tysabri (natalizumab) market is anticipated to experience robust expansion over the forthcoming years. Its valuation is projected to ascend to $3.87 million by 2030, demonstrating a compound annual growth rate (CAGR) of 7.8%. This growth during the forecast period can be ascribed to an increase in MS diagnosis rates, enhancements in infusion infrastructure, strengthened risk mitigation strategies, a rise in specialized neurology services, and supportive long-term clinical outcomes. Significant developments foreseen in this period include the expanding application of monoclonal antibodies in MS, a leaning towards highly effective disease-modifying therapies, the broadening availability of outpatient infusion care, refined safety and risk monitoring protocols, and an increasing focus on the management of progressive MS.
Get A Free Sample Report With In-Depth Market Insights:
Tysabri (natalizumab) Market Growth Catalysts And Demand Drivers
An anticipated increase in autoimmune disorders is projected to boost the expansion of the tysabri (natalizumab) market. These conditions occur when the immune system mistakenly attacks the body’s own tissues, cells, or organs, leading to inflammation, damage, and chronic ailments like rheumatoid arthritis or multiple sclerosis, resulting from a combination of genetic and environmental influences. The growing prevalence of autoimmune disorders stems from factors such as genetic susceptibility, environmental triggers, and enhanced diagnostic capabilities, leading to more identified cases. Tysabri effectively addresses autoimmune disorders by targeting specific immune cells, thereby preventing inflammation and damage and aiding in the treatment of conditions like multiple sclerosis and Crohn’s disease. For instance, in February 2024, Arthritis Australia, an Australia-based charitable not-for-profit organisation advocating for people with arthritis and musculoskeletal conditions, reported that by 2025, approximately 562,378 Australians are expected to be living with rheumatoid arthritis (RA), representing 14% of the total arthritis population. Consequently, the increasing occurrence of autoimmune disorders is a significant impetus for the tysabri (natalizumab) market’s growth. The advancement of personalized medicine is set to propel the growth trajectory of the tysabri (natalizumab) market. Personalized medicine involves a medical strategy that customizes treatment and healthcare plans according to each patient’s unique attributes, such as their genetic makeup, environment, and lifestyle, aiming for optimal and precise outcomes. This rise in personalized medicine is attributed to breakthroughs in genomic technologies, a deeper comprehension of molecular biology, the increasing availability of accurate diagnostic tools, and a demand for therapies that specifically target diseases, enhancing patient results while minimizing adverse reactions. Tysabri (natalizumab) serves as a prime example of personalized medicine principles by offering a focused treatment for relapsing forms of multiple sclerosis, tailored for patients displaying particular disease activity and risk profiles, thus maximizing its therapeutic effectiveness while mitigating potential negative effects. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, stated that the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, an increase from six in 2022. Additionally, this total included seven drugs designed for cancer treatment and three addressing various other diseases and conditions. Therefore, the expansion of personalized medicine is a key driver for the tysabri (natalizumab) market.
Tysabri (natalizumab) Market Segment Analysis Spotlighting Growth Areas
The tysabri (natalizumab) market covered in this report is segmented –
1) By Clinical Indication: Multiple Sclerosis, Crohn’s Disease
2) By Patient Setting: Inpatient, Outpatient
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Tysabri (natalizumab) Market Trends Shaping Long-Term Demand
Leading companies operating within the tysabri (natalizumab) market are prioritizing the expansion of treatment options through alternative solutions, such as biosimilars, to provide patients with more efficacious therapies that enhance their quality of life and improve disease management. Biosimilars to Tysabri offer a financially viable alternative for addressing highly active relapsing-remitting multiple sclerosis, thereby increasing access to essential care, especially in regions that are underserved. As an illustration, in January 2024, Sandoz Group AG, a pharmaceutical company headquartered in Switzerland, introduced Tyruko (natalizumab), which is the inaugural and sole biosimilar to Tysabri, intended for the treatment of adults with highly active relapsing-remitting multiple sclerosis (RRMS). This new offering reinforces Sandoz’s biosimilar product range and seeks to broaden access to impactful and economical treatments for individuals living with multiple sclerosis.
Tysabri (natalizumab) Market Leading Companies: Who Holds The Strongest Market Presence?
Major companies operating in the tysabri (natalizumab) market are Biogen Idec Inc., Sandoz International GmbH, Polpharma Biologics
View The Full Tysabri (natalizumab) Market Report:
Tysabri (natalizumab) Market Leading Geography: Which Region Contributes The Most Revenue?
North America was the largest region in the tysabri (natalizumab) market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tysabri (natalizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
